Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials
Wendy B. London; Rochelle Bagatell; Brenda J. Weigel; Elizabeth Fox; Dongjing Guo; Collin Van Ryn; Arlene Naranjo; Julie R. Park
Author Information: Dana‐Farber/Boston Children's Cancer and Blood Disorders Center, Department of Medicine, Harvard Medical School
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.